Prof. Dr. Felicitas Hitz
Stv. Chefärztin
Leitung Netzwerk
Leitung Bildung
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. Hematol Oncol 2018
03.08.2018Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
03.08.2018Hematol Oncol 2018
Aeppli Stefanie, Driessen Christoph, Graf Lukas, Hitz Felicitas
Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n
Lüscher D, Diethelm M, Hundsberger T, Hitz F. Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n. Praxis (Bern 1994) 2018; 107:329-333.
14.03.2018Fieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n
14.03.2018Praxis (Bern 1994) 2018; 107:329-333
Lüscher Daniel, Diethelm Markus, Hundsberger Thomas, Hitz Felicitas
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
20.10.2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
20.10.2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017
16.06.2017Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
16.06.2017Hematol Oncol 2017
Gobba Stefania, Gaidano Gianluca, Pinotti Graziella, Hitz Felicitas, Stathis Anastasios, Aprile von Hohenstaufen Kathrin, Margiotta-Casaluci Gloria, Iacoboni Gloria, Cascione Luciano, Diem Stefan, Conconi Annarita, Gulden-Sala Wiebke, Moccia Alden A, Zucca Emanuele
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, Stathis A, Fischer N, Clough-Gorr K. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. Support Care Cancer 2017; 25:2833-2842.
13.04.2017Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
13.04.2017Support Care Cancer 2017; 25:2833-2842
Ribi Karin, Rondeau Stephanie, Hitz Felicitas, Mey Ulrich, Enoiu Milica, Pabst Thomas, Stathis Anastasios, Fischer Natalie, Clough-Gorr Kerri M
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
16.12.2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
16.12.2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016; 17:1453-1462.
06.09.2016Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
06.09.2016Lancet Oncol 2016; 17:1453-1462
Kreissl Stefanie, Borchmann Peter, Engert Andreas, Diehl Volker, Fuchs Michael, Flechtner Hans-Henning, Rueffer Jens Ulrich, Shonukan Oluwatoyin, Soekler Martin, Hitz Felicitas, Halbsguth Teresa Veronika, Behringer Karolin, Brillant Corinne, Mayer Axel, Goergen Helen, Mueller Horst
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
28.07.2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
28.07.2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
15.04.2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
15.04.2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
28.03.2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
28.03.2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127:2189-92.
01.02.2016Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
01.02.2016Blood 2016; 127:2189-92
Böll Boris, Engert Andreas, Diehl Volker, Fuchs Michael, Borchmann Sven, Bürkle Carolin, Eichenauer Dennis A, von Tresckow Bastian, Greil Richard, Kerkhoff Andrea, Hitz Felicitas, Bröckelmann Paul J, Behringer Karolin, Goergen Helen, Borchmann Peter
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
Taverna C, Zucca E, Heijnen I, Rusterholz C, Rondeau S, Biaggi Rudolf C, Lohri A, Vorobiof D, Rauch D, Raats J, Laszlo D, Vanazzi A, Del Giglio A, Cevreska L, Pabst T, Mingrone W, Hitz F, Martinelli G, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol 2015; 34:495-500.
28.12.2015Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
28.12.2015J Clin Oncol 2015; 34:495-500
Taverna Christian, Zucca Emanuele, Heijnen Ingmar A F M, Rusterholz Corinne, Rondeau Stephanie, Biaggi Rudolf Christine, Lohri Andreas, Vorobiof Daniel A, Rauch Daniel, Raats Johann, Laszlo Daniele, Vanazzi Anna, Del Giglio Auro, Cevreska Lidija, Pabst Thomas, Mingrone Walter, Hitz Felicitas, Martinelli Giovanni, Ghielmini Michele
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
11.12.2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
11.12.2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
Hitz F, Villa D, Shenkier T, Sehn L, Savage K, Moccia A, Hoskins P, Gascoyne R, Connors J, Klasa R. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol 2015; 94:1839-43.
07.08.2015Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
07.08.2015Ann Hematol 2015; 94:1839-43
Hitz Felicitas, Villa D, Shenkier T, Sehn L H, Savage K J, Moccia A, Hoskins P, Gascoyne R D, Connors J M, Klasa R
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
06.07.2015Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
06.07.2015J Clin Oncol 2015; 33:2523-9
Mamot Christoph, Zucca Emanuele, Dirnhofer Stephan, Rusterholz Corinne, Biaggi Christine, Samarin Andrei, Hany Thomas, Gigli Federica, Krasniqi Fatime, Bargetzi Mario, Pless Miklos, Mey Ulrich, Driessen Christoph, Pabst Thomas, Renner Christoph, Hitz Felicitas, Klingbiel Dirk, Martinelli Giovanni
Improved survival of older patients with multiple myeloma in the era of novel agents
Mey U, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34:217-223.
21.04.2015Improved survival of older patients with multiple myeloma in the era of novel agents
21.04.2015Hematol Oncol 2015; 34:217-223
Mey Ulrich J M, Leitner Christoph, Driessen Christoph, Cathomas Richard, Klingbiel Dirk, Hitz Felicitas
Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
Weisshaupt C, Hitz F, Albrich W, Omlin A. Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading. BMJ Case Rep 2014; 2014
22.09.2014Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading
22.09.2014BMJ Case Rep 2014; 2014
Weisshaupt Christian, Hitz Felicitas, Albrich Werner, Omlin Aurelius
Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 2014; 25:577-82.
28.05.2014Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis
28.05.2014Eur J Intern Med 2014; 25:577-82
Diem Stefan, Ess S, Cerny Thomas, Früh Martin, Hitz Felicitas
Leptomeningeal lymphomatosis from large granular lymphocyte leukaemia
Hundsberger T, Weber J, Brügge D, Sédille-Mostafaie N, Hitz F. Leptomeningeal lymphomatosis from large granular lymphocyte leukaemia. J Neurol 2014; 261:1221-2.
30.04.2014Leptomeningeal lymphomatosis from large granular lymphocyte leukaemia
30.04.2014J Neurol 2014; 261:1221-2
Hundsberger Thomas, Weber Johannes, Brügge Detlef, Sédille-Mostafaie Nazanin, Hitz Felicitas
A hairy issue
Silzle T, Hitz F. A hairy issue. Blood 2014; 123:958.
13.02.2014A hairy issue
13.02.2014Blood 2014; 123:958
Silzle Tobias, Hitz Felicitas